Aldeyra Therapeutics, Inc.

“Pipeline in a pill”-style drug development will be on display in April, when more than half of the user fee goal dates are for new indications on sometimes sprawling labels, as well as one novel biol

While the FDA is facing a disrupted and uncharted future, drug development offers a few certainties, including that oncology and neuroscience still dominate the novel agents seeking approval. But the

The US Food and Drug Administration maintained a high rate of complete response letter actions for novel agent applications in 2024, but recent history suggests that many of the 16 CRL recipients will

Aldeyra Therapeutics, Inc. plans to resubmit reproxalap for US Food and Drug Administration approval to treat dry eye disease based on the positive outcome of a Phase III dye eye chamber clinical tri